Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis

Myelofibrosis is a hematopoietic stem cell disorder belonging to the myeloproliferative neoplasms. Myelofibrosis patients frequently carry driver mutations in either JAK2 or Calreticulin (CALR) and have limited therapeutic options. Here, we integrate ex vivo drug response and proteotype analyses acr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wildschut, Mattheus H. E., Mena, Julien, Dördelmann, Cyril, van Oostrum, Marc, Hale, Benjamin D., Settelmeier, Jens, Festl, Yasmin, Lysenko, Veronika, Schürch, Patrick M., Ring, Alexander, Severin, Yannik, Bader, Michael S., Pedrioli, Patrick G. A., Goetze, Sandra, van Drogen, Audrey, Balabanov, Stefan, Skoda, Radek C., Lopes, Massimo, Wollscheid, Bernd, Theocharides, Alexandre P. A., Snijder, Berend
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570306/
https://www.ncbi.nlm.nih.gov/pubmed/37828014
http://dx.doi.org/10.1038/s41467-023-42101-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570306/
https://www.ncbi.nlm.nih.gov/pubmed/37828014
http://dx.doi.org/10.1038/s41467-023-42101-z

Ejemplares similares